Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines
as the first-line option for the treatment of venous thromboembolism and prevention of stroke …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and
provide advantages over existing agents. As with all anticoagulants, management protocols …

Direct oral anticoagulants (DOACs) have been marketed in the United States since 2010.
While numerous large-scale prospective phase 3 outcomes studies have documented the …

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K
antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism …

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in the
prevention and treatment of venous thromboembolism and in the prevention of stroke in …

Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many
years for patients with AF and other thrombotic conditions. The introduction of direct oral …

Summary Background Direct oral anticoagulants (DOACs) are widely used as an alternative
for warfarin. However, the impact of DOACs on mortality outcomes compared with warfarin …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated
following the introduction of a new generation of direct oral anticoagulants (DOACs) …